PLYMOUTH
MEETING, Pa., Sept. 17,
2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-related
diseases, cancer, and infectious diseases, today announced
that it will present at the following scientific conference:
World Congress of Electroporation
Oral
Presentation by Trevor Smith, VP of
Preclinical R&D at INOVIO
Abstract Title: Development of in vivo-launched synthetic
DNA-encoded antibodies employing CELLECTRA® electroporation
technology
Date and Time: September 18, 2024,
3:20pm – 3:35pm CET
Location: Rome, Italy
The abstract from the conference will be made available on
INOVIO's website following the data presentation.
About INOVIO
INOVIO is a biotechnology company focused
on developing and commercializing DNA medicines to help treat and
protect people from HPV-related diseases, cancer, and infectious
diseases. INOVIO's technology optimizes the design and delivery of
innovative DNA medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
Contacts
Media: Jennie
Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conference-302250936.html
SOURCE INOVIO Pharmaceuticals, Inc.